The given review deals with infective endocarditis in pregnant women, which is a rare but severe cardiac complication that has a significant impact on the course of gestation and on the fetus. It touches upon the issues of the epidemiology and risk factors for the disease, which can expect the number of patients at high risk for infective endocarditis to rise during pregnancy. Special attention is paid to primary cardiac disease (congenital and rheumatic heart diseases, mitral valve prolapse, ventricular septal defect, the presence of an artificial valve, and previous infective endocarditis), to intravenous medications, various diseases, and manipulations, which increase the risk of infectious endocarditis, such as hemodialysis, obstetrical/gynecological, dental procedures, immunodeficiency states, etc.). The etiological pattern of the infectious agents that most commonly involve the valve apparatus, among which there is a preponderance of streptococcal and staphylococcal groups, is discussed. The clinical picture of infective endocarditis in pregnant women is presented as both the typical symptoms and signs characteristic of this disease and the specific features of clinical manifestations associated with pregnancy. The paper gives modified diagnostic criteria in view of the proposals made by the Working Group of the European Society of Cardiology (2015) and discusses the specific features of microbiological and imaging methods for the diagnosis of infective endocarditis in pregnant women. The course and complications of the disease and maternal and perinatal are highlighted in detail. The aspects of antimicrobial therapy are revealed on details with consideration, first of all, for the potential effect of antibiotics on the course of pregnancy and the development of a fetus. Indications and time for cardiac surgery, the principles of anticoagulant therapy and labor management are discussed. Current views on the antimicrobial prevention of infective endocarditis during pregnancy are presented. The authors declare no conflicts of interest.